MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.20.01366

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.

Nowakowski Grzegorz S, Chiappella Annalisa, Gascoyne Randy D, Scott David W, Zhang Qingyuan, Jurczak Wojciech, Özcan Muhit, Hong Xiaonan, Zhu Jun, Jin Jie, Belada David, Bergua Juan Miguel, Piazza Francesco, Mócikova Heidi, Molinari Anna Lia, Yoon Dok Hyun, Cavallo Federica, Tani Monica, Yamamoto Kazuhito, Izutsu Koji, Kato Koji, Czuczman Myron, Hersey Sarah, Kilcoyne Adrian, Russo Jacqueline, Hudak Krista, Zhang Jingshan, Wade Steve, Witzig Thomas E, Vitolo Umberto

Клиническое исследование III фазыСравнительное исследованиеСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Phase II studies demonstrated that adding the immunomodulatory agent lenalidomide to R-CHOP improved outcomes in ABC-type DLBCL. The goal of the global, phase III ROBUST study was to compare lenalidomide plus R-CHOP (R2-CHOP) with placebo/R-CHOP in previously untreated, ABC-type DLBCL.

METHODS

Histology and cell-of-origin type were prospectively analyzed by central pathology prior to random assignment and study treatment. Patients with ABC-DLBCL received lenalidomide oral 15 mg/d, days 1-14/21 plus standard R-CHOP21 versus placebo/R-CHOP21 for six cycles. The primary end point was progression-free survival (PFS) per independent central radiology review.

RESULTS

A total of 570 patients with ABC-DLBCL (n = 285 per arm) were stratified by International Prognostic Index score, age, and bulky disease, and randomly assigned to R2-CHOP or placebo/R-CHOP. Baseline demographics were similar between arms. Most patients completed six cycles of treatment: 74% R2-CHOP and 84% placebo/R-CHOP. The most common grade 3/4 adverse events for R2-CHOP versus placebo/R-CHOP were neutropenia (60% v 48%), anemia (22% v 14%), thrombocytopenia (17% v 11%), and leukopenia (14% v 15%). The primary end point of PFS was not met, with a hazard ratio of 0.85 (95% CI, 0.63 to 1.14) and P = .29; median PFS has not been reached for either arm. PFS trends favoring R2-CHOP over placebo/R-CHOP were seen in patients with higher-risk disease.

CONCLUSION

ROBUST is the first DLBCL phase III study to integrate biomarker-driven identification of eligible ABC patients. Although the ROBUST trial did not meet the primary end point of PFS in all patients, the safety profile of R2-CHOP was consistent with individual treatments with no new safety signals.

Для цитирования: Nowakowski Grzegorz S, Chiappella Annalisa, Gascoyne Randy D, Scott David W, Zhang Qingyuan, Jurczak Wojciech, Özcan Muhit, Hong Xiaonan, Zhu Jun, Jin Jie, Belada David, Bergua Juan Miguel, Piazza Francesco, Mócikova Heidi, Molinari Anna Lia, Yoon Dok Hyun, Cavallo Federica, Tani Monica, Yamamoto Kazuhito, Izutsu Koji, Kato Koji, Czuczman Myron, Hersey Sarah, Kilcoyne Adrian, Russo Jacqueline, Hudak Krista, Zhang Jingshan, Wade Steve, Witzig Thomas E, Vitolo Umberto. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021. DOI: 10.1200/jco.20.01366.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.